D. Ricard, A. Idbaih, F. Ducray, M. Lahutte, K. Hoang-xuan et al., Primary brain tumours in adults, Lancet, vol.379, issue.9830, pp.1984-96, 2012.

L. Bauchet, V. Rigau, H. Mathieu-daudé, D. Figarella-branger, D. Hugues et al., French brain tumor data bank: methodology and first results on 10,000 cases, J. Neurooncol, vol.84, issue.2, pp.189-99, 2007.

Q. T. Ostrom, H. Gittleman, J. Fulop, M. Liu, R. Blanda et al., CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States, Neuro-Oncology, vol.17, issue.4, pp.1-62, 2008.

D. W. Parsons, S. Jones, and X. Zhang, An integrated genomic analysis of human glioblastoma multiforme, Science, vol.321, pp.1807-1819, 2008.

H. Yan, R. Mclendon, I. Kos, G. J. Riggins, D. Reardon et al., IDH1 and IDH2 Mutations in Gliomas, The New England Journal of Medicine, vol.9, 2009.

B. E. Johnson, T. Mazor, C. Hong, M. Barnes, K. Aihara et al., Mutational Analysis Reveals the Origin and Therapy-driven Evolution of Recurrent Glioma, Science, vol.343, issue.6167, pp.189-193, 2014.

C. Zhang, L. M. Moore, X. Li, W. Yung, and W. Zhang, IDH1/2 mutations target a key hallmark of cancer by deregulating cellular metabolism in glioma, Neuro-Oncology. sept, vol.15, issue.9, pp.1114-1140, 2013.

T. Watanabe, S. Nobusawa, P. Kleihues, and H. Ohgaki, IDH1 Mutations Are Early Events in the Development of Astrocytomas and Oligodendrogliomas, The American Journal of Pathology. avr, vol.174, issue.4, pp.1149-53, 2009.

D. N. Louis, A. Perry, G. Reifenberger, A. Von-deimling, D. Figarella-branger et al., The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary, Acta Neuropathologica, vol.131, issue.6, pp.803-820, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01479018

P. Wesseling, M. Van-den-bent, and A. Perry, Oligodendroglioma: pathology, molecular mechanisms and markers, Acta Neuropathologica. juin, vol.129, issue.6, pp.809-836, 2015.

D. Khuong-quang, P. Buczkowicz, P. Rakopoulos, X. Liu, A. M. Fontebasso et al., K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas, Acta Neuropathologica, vol.124, issue.3, pp.439-447, 2012.

J. Amorim, G. Santos, J. Vinagre, and P. Soares, The Role of ATRX in the Alternative Lengthening of Telomeres (ALT) Phenotype. Genes, vol.7, p.66, 2016.

K. M. Walsh, J. K. Wiencke, D. H. Lachance, J. L. Wiemels, A. M. Molinaro et al., Telomere maintenance and the etiology of adult glioma, Neuro-Oncology, vol.17, issue.11, pp.1445-52, 2015.

G. Wu, A. K. Diaz, B. S. Paugh, S. L. Rankin, B. Ju et al., The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma, Nature Genetics, vol.46, issue.5, pp.444-450, 2014.

M. Weller, MGMT promoter methylation in malignant gliomas : ready for personalized medicine, Nat Rev Neurol, 2010.

M. Weller, R. Stupp, G. Reifenberger, A. A. Brandes, M. J. Van-den-bent et al., MGMT promoter methylation in malignant gliomas: ready for personalized medicine?, Nature Reviews Neurology, vol.6, issue.1, pp.39-51, 2009.

M. Weller, M. Van-den-bent, J. C. Tonn, R. Stupp, M. Preusser et al., European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas, The Lancet Oncology, vol.18, issue.6, pp.30194-30202, 2017.

W. Stummer, M. J. Van-den-bent, and M. Westphal, Cytoreductive surgery of glioblastoma as the key to successful adjuvant therapies : new arguments in an old discussion, Acta Neurochir (Wien), vol.153, pp.1211-1229, 2011.

P. C. De-witt-hamer, S. G. Robles, A. H. Zwinderman, H. Duffau, and M. S. Berger, Impact of intraoperative stimulation brain mapping on glioma surgery outcome: a metaanalysis, J Clin Oncol, vol.30, pp.2559-65, 2012.

J. C. Buckner, E. G. Shaw, and S. L. Pugh, Radiation plus procarbazine, CCNU, and vincristine in low-grade glioma, N Engl J Med, vol.374, pp.1344-55, 2016.

M. J. Van-den-bent, A. A. Brandes, and M. J. Taphoorn, Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951, J Clin Oncol, vol.31, pp.344-50, 2013.

R. Stupp, M. E. Hegi, W. P. Mason, and M. J. Van-den-bent, Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival inglioblastoma in a randomised phase III study : 5-year analysis of the EORTC-NCIC trial, Lancet Oncol, vol.10, pp.459-66, 2009.

M. Van-den-bent, B. Baumert, and S. C. Erridge, Concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: interim results of the randomized intergroup CATNON trial (EORTC study, pp.26053-22054

, Lancet

J. R. Perry, N. Laperriere, and C. J. O'callaghan, Short-course radiation plus temozolomide in elderly patients with glioblastoma, N Engl J Med, vol.376, pp.1027-1064, 2017.

K. Aldape, G. Zadeh, S. Mansouri, G. Reifenberger, and A. Deimling, Glioblastoma: pathology, molecular mechanisms and markers, Acta Neuropathologica, vol.129, issue.6, pp.829-848, 2015.

A. P. Kyritsis, M. L. Bondy, J. S. Rao, and C. Sioka, Inherited predisposition to glioma, Neuro Oncol, vol.12, pp.104-113, 2010.

J. G. Cairncross, M. Wang, R. B. Jenkins, E. G. Shaw, C. Giannini et al., Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors is associated with mutation of IDH, J. Clin Oncol Mar, vol.10, issue.8, pp.783-90, 2014.

C. Hartmann, J. Meyer, J. Balss, D. Capper, W. Mueller et al., Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas, Acta Neuropathologica, vol.118, issue.4, pp.469-74, 2009.

D. Meyronet, M. Esteban-mader, C. Bonnet, M. Joly, E. Uro-coste et al., Characteristics of H3 K27M-mutant gliomas in adults, Neuro-Oncology, vol.19, issue.8, pp.1127-1134, 2017.

T. Watanabe, A. Vital, S. Nobusawa, P. Kleihues, and H. Ohgaki, Selective acquisition of IDH1 R132C mutations in astrocytomas associated with Li-Fraumeni syndrome, Acta Neuropathologica. juin, vol.117, issue.6, pp.653-659, 2009.

J. Hayes, Y. Yu, L. E. Jalbert, T. Mazor, L. E. Jones et al., Genomic analysis of the origins and evolution of multicentric diffuse lower-grade gliomas, Neuro-Oncology. 9 avr, vol.20, issue.5, pp.632-673, 2018.

C. Bonnet, L. Thomas, D. Psimaras, F. Bielle, E. Vauléon et al., Characteristics of gliomas in patients with somatic IDH mosaicism, Acta Neuropathologica Communications, vol.4, issue.1, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01297851

J. Akimoto, H. Sasaki, R. Haraoka, N. Nakajima, S. Fukami et al., A case of radiologically multicentric but genetically identical multiple glioblastomas, Brain Tumor Pathology. avr, vol.31, issue.2, pp.113-120, 2014.

F. Galuppini, E. Opocher, U. Tabori, I. Mammi, M. Edwards et al.,

, Concomitant IDH wild-type glioblastoma and IDH1 -mutant anaplastic astrocytoma in a patient with constitutional mismatch repair deficiency syndrome, Neuropathology and Applied Neurobiology. févr, vol.44, issue.2, pp.233-242, 2018.

G. Lombardi, D. Puppa, A. Gardiman, M. P. Rossi, S. Candiotto et al., Discordance of IDH mutational status between lesions in an adult patient with multifocal glioma, Neuro-Oncology. 5 juill, vol.20, issue.8, pp.1142-1145, 2018.

R. Appay, E. Tabouret, N. Macagno, M. Touat, C. Carpentier et al., IDH2 mutations are commonly associated with 1p/19q codeletion in diffuse adult gliomas, Neuro-Oncology, 2018.
URL : https://hal.archives-ouvertes.fr/hal-01775166

A. Picca, G. Berzero, F. Bielle, M. Touat, J. Savatovsky et al., FGFR1 actionable mutations, molecular specificities, and outcome of adult midline gliomas, Neurology. 5 juin, vol.90, issue.23, pp.2086-94, 2018.
URL : https://hal.archives-ouvertes.fr/hal-01971530

E. Tabouret, A. T. Nguyen, C. Dehais, C. Carpentier, F. Ducray et al., Prognostic impact of the 2016 WHO classification of diffuse gliomas in the French POLA cohort, Acta Neuropathologica, vol.132, issue.4, pp.625-634, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01480146

S. Chotirat, W. Thongnoppakhun, O. Promsuwicha, C. Boonthimat, and C. U. Auewarakul, Molecular alterations of isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) metabolic genes and additional genetic mutations in newly diagnosed acute myeloid leukemia patients, Journal of Hematology & Oncology, vol.5, issue.1, p.5, 2012.

L. N. Toth, F. B. De-abreu, and L. J. Tafe, Non-small cell lung cancers with isocitrate dehydrogenase 1 or 2 (IDH1/2) mutations, Human Pathology. août, vol.78, pp.138-181, 2018.

J. E. Eckel-passow, D. H. Lachance, A. M. Molinaro, K. M. Walsh, P. A. Decker et al., Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors, N Engl J Med, vol.372, pp.2499-2508, 2015.

K. Labreche, B. Kinnersley, G. Berzero, D. Stefano, A. L. Rahimian et al., Diffuse gliomas classified by 1p/19q co-deletion, TERT promoter and IDH mutation status are associated with specific genetic risk loci, Acta Neuropathologica. mai, vol.135, issue.5, pp.743-55, 2018.
URL : https://hal.archives-ouvertes.fr/hal-01974524

A. P. Kyritsis, M. L. Bondy, J. S. Rao, and C. Sioka, Inherited predisposition to glioma, Neuro Oncol, vol.12, pp.104-113, 2010.

R. B. Jenkins, Y. Xiao, H. Sicotte, P. A. Decker, T. M. Kollmeyer et al., A low-frequency variant at 8q24.21 is strongly associated with risk of oligodendroglial tumors and astrocytomas with IDH1 or IDH2 mutation, Nature Genetics, vol.44, issue.10, pp.1122-1127, 2012.

S. Braunstein, D. Raleigh, R. Bindra, S. Mueller, and D. Haas-kogan, , 2017.

, Pediatric high-grade glioma: current molecular landscape and therapeutic approaches, Journal of Neuro-Oncology, vol.134, issue.3, pp.541-549

V. M. Lu and K. L. Mcdonald, Isocitrate dehydrogenase 1 mutation subtypes at site 132 and their translational potential in glioma, CNS Oncology. janv, vol.7, issue.1, pp.41-50, 2018.

K. Auré, F. Laigle-donadey, G. Kaloshi, A. Amiel-benouaich, and M. Sanson, Les gliomes multiples : étude clinique et hypothèses physiopathologiques, Revue Neurologique, vol.162, issue.8-9, pp.845-851, 2006.

M. C. Chamberlain, Salvage therapy with BRAF inhibitors for recurrent pleomorphic xanthoastrocytoma: a retrospective case series, J Neurooncol, vol.114, pp.237-277, 2013.

G. Schindler, D. Capper, and J. Meyer, Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma, Acta Neuropathol, vol.121, pp.397-405, 2011.

K. E. Yen, M. A. Bittinger, S. M. Su, and V. R. Fantin, Cancer-associated IDH mutations: biomarker and therapeutic opportunities, Oncogene. déc, vol.29, issue.49, pp.6409-6426, 2010.

M. Weller, S. M. Pfister, W. Wick, M. E. Hegi, G. Reifenberger et al., Molecular neuro-oncology in clinical practice: a new horizon, The Lancet Oncology. août, vol.14, issue.9, pp.370-379, 2013.

M. J. Van-den-bent, H. J. Dubbink, M. Sanson, C. R. Van-der-lee-haarloo, M. Hegi et al., Promoter Methylation Is Prognostic but Not Predictive for Outcome to Adjuvant PCV Chemotherapy in Anaplastic Oligodendroglial Tumors: A Report From EORTC Brain Tumor Group Study 26951, Journal of Clinical Oncology. 10 déc, vol.27, issue.35, pp.5881-5887, 2009.

J. Koh, H. Cho, H. Kim, S. I. Kim, S. Yun et al., , 2014.

, IDH2mutation in gliomas including novel mutation, Neuropathology, vol.35, issue.3, pp.236-244

L. M. Wang, Z. Li, Y. S. Piao, Y. N. Cai, L. Y. Zhang et al., Cliniconeuropathological features of isocitrate dehydrogenase 2 gene mutations in lower-grade gliomas, Chin Med J, vol.132, pp.2920-2926, 2019.

S. Busch, S. Krausert, and V. Fischer, Von Deimling A. Pan-mutant IDH1 inhibitor BAY 1436032 for effective treatment of IDH1 mutant astrocytoma in vivo, Acta Neuropathol, vol.133, issue.4, pp.629-644, 2017.

K. Awoke and A. Netsuke, Overview of DNA methylation in adult diffuse gliomas, Brain Tumor Pathol, vol.36, issue.2, pp.84-91, 2019.

, Serment d'Hippocrate

, Au moment d'être admise à exercer la médecine, je promets et je jure d'être fidèle aux lois de l'honneur et de la probité

, Mon premier souci sera de rétablir, de préserver ou de promouvoir la santé dans tous ses éléments, physiques et mentaux, individuels et sociaux

, Je respecterai toutes les personnes, leur autonomie et leur volonté, sans aucune discrimination selon leur état ou leurs convictions. J'interviendrai pour les protéger si elles sont affaiblies, vulnérables ou menacées dans leur intégrité ou leur dignité. Même sous la contrainte

, Je ne tromperai jamais leur confiance et n'exploiterai pas le pouvoir hérité des

, Admise dans l'intimité des personnes, je tairai les secrets qui me seront confiés. Reçue à l'intérieur des maisons, je respecterai les secrets des foyers et ma conduite ne servira pas à corrompre les moeurs

, Je ne prolongerai pas abusivement les agonies. Je ne provoquerai jamais la mort délibérément

, Je n'entreprendrai rien qui dépasse mes compétences. Je les entretiendrai et les perfectionnerai pour assurer au mieux les services qui me seront demandés

, J'apporterai mon aide à mes confrères ainsi qu'a? leurs familles dans l'adversité

, Que les hommes et mes confrères m'accordent leur estime si je suis fidèle à mes promesses ; que je sois déshonorée et méprisée si j'y manque